ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,938,748 | -13.1% | 218,819 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $6,830,520 | -35.0% | 222,203 | -23.8% | 0.00% | -40.0% |
| Q1 2023 | $10,502,961 | +66.0% | 291,506 | +82.1% | 0.01% | +66.7% |
| Q4 2022 | $6,326,243 | -51.7% | 160,077 | -50.9% | 0.00% | -50.0% |
| Q3 2022 | $13,109,000 | -19.4% | 326,259 | -15.7% | 0.01% | -14.3% |
| Q2 2022 | $16,272,000 | +29.4% | 387,059 | +19.9% | 0.01% | +40.0% |
| Q1 2022 | $12,572,000 | +101.5% | 322,699 | +106.1% | 0.01% | +150.0% |
| Q4 2021 | $6,239,000 | +8.0% | 156,570 | -2.1% | 0.00% | 0.0% |
| Q3 2021 | $5,778,000 | -11.2% | 159,879 | +0.7% | 0.00% | -33.3% |
| Q2 2021 | $6,510,000 | +60.3% | 158,809 | +70.6% | 0.00% | +50.0% |
| Q1 2021 | $4,060,000 | +61.7% | 93,087 | +85.5% | 0.00% | +100.0% |
| Q4 2020 | $2,511,000 | +46.6% | 50,172 | +23.2% | 0.00% | 0.0% |
| Q3 2020 | $1,713,000 | – | 40,712 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |